This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
by Zacks Equity Research
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River Stock May Gain From Extended CHDI Research Deal on HD
by Zacks Equity Research
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
Should You Continue to Hold Charles River Stock in Your Portfolio?
by Zacks Equity Research
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Understanding Charles River (CRL) Reliance on International Revenue
by Zacks Equity Research
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
by Zacks Equity Research
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 13.59% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
by Zacks Equity Research
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
by Zacks Equity Research
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?
by Zacks Equity Research
Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
by Zacks Equity Research
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphering Charles River (CRL) International Revenue Trends
by Zacks Equity Research
Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
by Zacks Equity Research
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 6.40% and 2.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.